Development consulting and scientific affairs firm PharmaLex Group has expanded its regulatory team with the addition of Zabin Younes.
She joins the group as an associate director and arrives from ERA Consulting – a biopharmaceutical consultancy based in the UK – where she picked up experience in the biosimilar development lifecycle.
“We are aware that biosimilars continue to be a key area for many biopharmaceutical companies and are continuing to strengthen our team to ensure we remain a leading service provider and Zabin comes to us with a wealth of experience,” said Dr Thomas Dobmeyer, CEO of PharmaLex.
“Enhancing our service lines with experts who are at the top of their industry is a key attraction for our clients. It allows us to provide instant access to specialist knowledge helping clients to reduce timelines,” he added.
With experience spanning over 15 years, Younes’ expertise includes CMC regulatory strategies, monoclonal antibody biosimilars, developing and implementing global regulatory strategies, scientific advice and pre-submission activities.
In addition she also has over ten years of management experience and has set up and managed research teams, GMP testing laboratories and led MHRA/FDA corporate audits.